<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03346434</url>
  </required_header>
  <id_info>
    <org_study_id>R668-AD-1539</org_study_id>
    <secondary_id>2016-000955-28</secondary_id>
    <nct_id>NCT03346434</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to &lt;6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)</brief_title>
  <acronym>Liberty AD</acronym>
  <official_title>A Phase 2/3 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Dupilumab in Patients Aged ≥6 Months to &lt;6 Years With Moderate-to-Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a 2-part (parts A and B) phase 2/3 study to evaluate the safety,&#xD;
      pharmacokinetics (PK) and efficacy of dupilumab in participants 6 months to less than 6 years&#xD;
      of age with moderate-to-severe atopic dermatitis (AD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Part A (open-label, single-ascending-dose, sequential cohort phase 2 study):&#xD;
&#xD;
             -  Primary objective is to characterize the safety and PK of dupilumab administered as&#xD;
                a single dose in pediatric participants, 6 months to less than 6 years of age, with&#xD;
                severe AD.&#xD;
&#xD;
             -  Secondary objective is to evaluate the efficacy and immunogenicity of a single dose&#xD;
                of dupilumab in participants 6 months to less than 6 years of age with severe AD.&#xD;
&#xD;
        2. Part B (randomized, double-blind, parallel-group, placebo-controlled phase 3 study):&#xD;
&#xD;
             -  Primary objective is to demonstrate the efficacy of multiple doses of dupilumab&#xD;
                over 16 weeks of treatment when administered concomitantly with topical&#xD;
                corticosteroids (TCS) in pediatric participants, 6 months to less than 6 years of&#xD;
                age, with moderate-to-severe AD.&#xD;
&#xD;
             -  Secondary objective is to assess the safety and immunogenicity of multiple doses of&#xD;
                dupilumab over 16 weeks of treatment when administered concomitantly with TCS in&#xD;
                participants 6 months to less than 6 years of age with moderate-to-severe AD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2017</start_date>
  <completion_date type="Actual">July 8, 2021</completion_date>
  <primary_completion_date type="Actual">July 8, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Part A: Single-ascending-dose cohorts staggered by age;&#xD;
Part B: Parallel Group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Part A: Open Label;&#xD;
Part B: Masked, Randomized</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Concentration of total dupilumab in serum over time and pharmacokinetic (PK) parameters</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>Summary statistics of drug concentration and PK parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Incidence of Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>TEAEs include adverse events (AEs), serious adverse events (SAEs), deaths, and laboratory abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Proportion of participants with an Investigator Global Assessment (IGA) score of 0 to 1</measure>
    <time_frame>At week 16</time_frame>
    <description>The Investigator's Global Assessment is a static 5-point measure of disease severity based on an overall assessment of the skin lesions. Scoring Ranges from 0 = Clear to 4 = severe disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: For European Medicines Agency (EMA) only: Proportion of participants with Eczema Area and Severity Index (EASI) -75 (≥75% improvement from baseline)</measure>
    <time_frame>At week 16</time_frame>
    <description>The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD (Hanifin 2001). The EASI is a composite index with scores ranging from 0 to 72</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: For EMA only: Proportion of participants with an IGA score of either 0 or 1</measure>
    <time_frame>At week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline to week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Incidence of severe TEAEs</measure>
    <time_frame>Baseline to week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Percent change in EASI score</measure>
    <time_frame>Baseline to week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Percent change in SCORing Atopic Dermatitis (SCORAD) score</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>SCORAD is a validated scoring index for AD, which combines A: extent (0-100), B: severity (0-18), and C: subjective symptoms (0-20) based on pruritus and sleep loss, each scored (0-10). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Proportion of participants with an IGA score of either 0 or 1</measure>
    <time_frame>At week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Determine immunogenicity titer</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>Assessed by measurement of anti-drug antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Not applicable for EMA: Proportion of participants with EASI-75 (≥75% improvement from baseline)</measure>
    <time_frame>At week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Percent change in EASI score</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Percent change in weekly average of daily worst scratch/itch numeric rating score (NRS)</measure>
    <time_frame>Baseline to week 16</time_frame>
    <description>The NRS is an 11-point scale (0 to 10) in which 0 indicates no scratching/itching while 10 indicates worst scratching/itching possible</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Proportion of participants with EASI-50 (≥50% improvement from baseline)</measure>
    <time_frame>At week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Proportion of participants with EASI-90 (≥90% improvement from baseline)</measure>
    <time_frame>At week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change in percent Body Surface Area (BSA) affected by AD</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Percent change in SCORAD</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change in weekly average of daily worst scratch/itch NRS score</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Proportion of participants with improvement (reduction) of weekly average of daily worst scratch/itch NRS score ≥4</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Proportion of participants with improvement (reduction) of weekly average of daily worst scratch/itch NRS score ≥3</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change in skin pain NRS</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change in sleep quality NRS</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change in health-related quality of life, as measured by Childrens' Dermatology Life Quality Index (CDLQI) (participants ≥4 years of age) and Infants' Dermatology Quality of Life Index (IDQOL) (participants &lt;4 years of age)</measure>
    <time_frame>Baseline to week 16</time_frame>
    <description>CDLQI is a quality of life questionnaire associated with atopic dermatitis (for participants &lt;4 years of age). Scoring ranges from 0 = unanswered to 3 = very much. IDQOL is a quality of life questionnaire associated with atopic dermatitis (for patients &lt;4 years of age). Scoring ranges from 0 (minimum impact) to 3 (maximum impact). The higher the sum of the scores, the greater the impact is on the QOL for CDLQI and IDQOL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change in Dermatitis Family Index (DFI)</measure>
    <time_frame>Baseline to week 16</time_frame>
    <description>DFI is a 10-item quality of family life questionnaire associated with atopic dermatitis. Scores range from 0 - 3. The higher the sum of the scores the greater the impact in family QOL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change in Patient Oriented Eczema Measure (POEM)</measure>
    <time_frame>Baseline to week 16</time_frame>
    <description>POEM is a 7-item, validated questionnaire used in clinical practice and clinical trials to assess disease symptoms in children and adults. Scoring ranges from 0 = no days to 4 = all days. Scoring system of 0 to 28; the total score reflects disease-related morbidity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Topical treatment for AD - proportion of topical corticosteroids (TCS) medication-free days</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Mean weekly dose of low potency TCS</measure>
    <time_frame>Up to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Mean of caregiver missed workdays</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Incidence of skin infection TEAEs</measure>
    <time_frame>Up to week 16</time_frame>
    <description>Excluding herpetic infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Incidence of SAEs through week 16</measure>
    <time_frame>Up to week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <arm_group>
    <arm_group_label>Part A (Open label Dupilumab): Age cohorts 1 &amp; 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Age cohort 1: ≥2 years old to &lt;6 years old&#xD;
Age cohort 2: ≥6 months to &lt;2 years old</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (Double-blind): Dupilumab dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The results of part A will be used to guide the selection of dose levels and dosing frequency for part B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (Double-blind): Dupilumab dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The results of part A will be used to guide the selection of dose levels and dosing frequency for part B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (Double-Blind): Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dupilumab</intervention_name>
    <description>Solution for injection, subcutaneous (SC)</description>
    <arm_group_label>Part A (Open label Dupilumab): Age cohorts 1 &amp; 2</arm_group_label>
    <arm_group_label>Part B (Double-blind): Dupilumab dose 1</arm_group_label>
    <arm_group_label>Part B (Double-blind): Dupilumab dose 2</arm_group_label>
    <other_name>DUPIXENT®</other_name>
    <other_name>REGN668</other_name>
    <other_name>SAR231893</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo</intervention_name>
    <description>Solution for injection, subcutaneous (SC)</description>
    <arm_group_label>Part B (Double-Blind): Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria&#xD;
&#xD;
          -  Diagnosis of atopic dermatitis (AD) according to the American Academy of Dermatology&#xD;
             consensus criteria at the screening visit&#xD;
&#xD;
          -  Participants with documented recent history (within 6 months before the screening&#xD;
             visit) of inadequate response to topical AD medication(s)&#xD;
&#xD;
          -  IGA score at screening and baseline visits&#xD;
&#xD;
          -  part A: IGA = 4&#xD;
&#xD;
          -  part B: IGA ≥3&#xD;
&#xD;
          -  EASI score at screening and baseline visits&#xD;
&#xD;
          -  part A: EASI ≥21&#xD;
&#xD;
          -  part B: EASI ≥16&#xD;
&#xD;
          -  Body Surface Area (BSA) involvement at screening and baseline visits&#xD;
&#xD;
          -  part A: ≥15%&#xD;
&#xD;
          -  part B: ≥10%&#xD;
&#xD;
          -  At least 11 (of a total of 14*) applications of a topical emollient (moisturizer)&#xD;
             during the 7 consecutive days immediately before the baseline visit (not including the&#xD;
             day of randomization) (for part B of the study only)&#xD;
&#xD;
          -  Baseline worst scratch/itch score weekly average score for maximum scratch/itch&#xD;
             intensity ≥4 (for part B of the study only)&#xD;
&#xD;
          -  At least 11 (of a total of 14) daily applications of low potency TCS during the 2-week&#xD;
             TCS standardization period (beginning on day -14) leading up to the baseline visit&#xD;
             (for part B of the study only).&#xD;
&#xD;
        Key Exclusion Criteria&#xD;
&#xD;
          -  Prior treatment with dupilumab&#xD;
&#xD;
          -  History of important side effects of low potency topical corticosteroids (only&#xD;
             applicable for part B of the study)&#xD;
&#xD;
          -  Having used immunosuppressive/immunomodulating drugs within 4 weeks before the&#xD;
             baseline visit&#xD;
&#xD;
          -  Treatment with a live (attenuated) vaccine within 4 weeks before the baseline visit&#xD;
&#xD;
          -  Active chronic or acute infection requiring treatment with systemic antibiotics,&#xD;
             antivirals, antiprotozoals, or antifungals within 2 weeks before the baseline visit.&#xD;
&#xD;
          -  Known or suspected immunodeficiency, known history of human immunodeficiency virus&#xD;
             (HIV) infection or HIV seropositivity at the screening visit, established diagnosis of&#xD;
             HBV infection or HBV seropositivity at screening, established diagnosis of HCV&#xD;
             infection or HCV seropositivity at screening&#xD;
&#xD;
          -  History of malignancy at any time before the baseline visit&#xD;
&#xD;
          -  Diagnosed active endoparasitic infections or at high risk of these infections&#xD;
&#xD;
          -  Severe concomitant illness(es) that, in the investigator's judgment, would adversely&#xD;
             affect the patient's participation in the study&#xD;
&#xD;
          -  Body weight &lt;5 kg or ≥30 kg at baseline (only applicable part B of the study)&#xD;
&#xD;
        Note: Other protocol defined Inclusion/ Exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-3807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>39328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104-1003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Forest Hills</city>
        <state>New York</state>
        <zip>113756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Osnabrück</city>
        <state>Lower Saxony</state>
        <zip>49074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational site</name>
      <address>
        <city>Muenster</city>
        <state>North Rhine-Westphal</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational site</name>
      <address>
        <city>Frankfurt/ Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational site</name>
      <address>
        <city>Muenchen</city>
        <zip>80802</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-453</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-648</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-011</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Ostrowiec Swietokrzyski</city>
        <zip>27-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01-142</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01-817</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Lancashire</state>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 6, 2017</study_first_submitted>
  <study_first_submitted_qc>November 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eczema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

